Lincoln Medical Center, New York (NY), USA.
Ateneo de Manila School of Medicine and Public Health, Pasig City, Philippines.
J ASEAN Fed Endocr Soc. 2024;39(1):69-78. doi: 10.15605/jafes.039.01.03. Epub 2023 Oct 27.
Sarcopenia refers to an age-related reduction of lean body mass. It showed a reciprocal relationship with cardiovascular diseases. Thus, it is imperative to explore pathophysiological mechanisms explaining the relationship between sarcopenia and cardiovascular diseases, along with the clinical assessment, and associated management. In this review, we discuss how processes such as inflammation, oxidative stress, endothelial dysfunction, neural and hormonal modifications, as well as other metabolic disturbances influence sarcopenia as well as its association with cardiovascular diseases. Moreover, this review provides an overview of both non-pharmacological and pharmacological management for patients with sarcopenia and cardiovascular diseases, with a focus on the potential role of cardiovascular drugs to mitigate sarcopenia.
肌少症是指与年龄相关的去脂体重减少。它与心血管疾病呈反比关系。因此,探索解释肌少症与心血管疾病之间关系的病理生理机制,以及临床评估和相关管理至关重要。在这篇综述中,我们讨论了炎症、氧化应激、内皮功能障碍、神经和激素改变以及其他代谢紊乱等过程如何影响肌少症及其与心血管疾病的关联。此外,本综述还概述了肌少症和心血管疾病患者的非药物和药物治疗方法,重点介绍了心血管药物减轻肌少症的潜在作用。